New drug for severe eczema is successful in two Phase 3 clinical trials: nearly 40% of patients receiving the drug - dupilumab, a monoclonal antibody inhibiting IL4 and IL13 signaling - had complete or near complete remission of symptoms.

See the source article by following the link below:
New drug for severe eczema is successful in two Phase 3 clinical trials: nearly 40% of patients receiving the drug - dupilumab, a monoclonal antibody inhibiting IL4 and IL13 signaling - had complete or near complete remission of symptoms.